Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
31 March 2020 | Story Leonie Bolleurs | Photo Gerhard de Jager
Prof Linda Basson recently returned from a three-month research expedition in Antarctica. Here she is, relaxing on the ice with the ever-inquisitive Adelie penguins having a gander at these strangers in their snowy world.
Prof Linda Basson recently returned from a three-month research expedition in Antarctica. Here she is, relaxing on the ice with the ever-inquisitive Adelie penguins having a gander at these strangers in their snowy world.

Very little is known about the parasites of Antarctica, which is a highly productive part of the oceans. These small organisms can be used very successfully to determine the health of this fragile ecosystem.

“Our research data can make significant contributions to the biodiversity of parasites, for a start. The data can also be very valuable to indicate the overall health of this large ecosystem – an ecosystem that drives many of the life-giving processes on our planet.” This is the belief of Prof Linda Basson from the Department of Zoology and Entomology at the University of the Free State (UFS). 

She is an aquatic parasitologist who concentrates on various parasites from a wide range of hosts, including vertebrates (fish and amphibians) and invertebrates (plankton, urchins, starfish, sea cucumbers and red-bait).

Prof Basson, together with PhD student Gerhard de Jager, was invited by Prof Isabelle Ansorge, Head of the School of Oceanography, University of Cape Town, to join her research team on the South African National Antarctic Programme (SANAE) Voyage 59 to Antarctica. 

Widen the scope of research 
“Our aim on this trip was to determine how we can collaborate with the various oceanographers to widen the scope of research normally performed on these voyages, in order to also include parasitological aspects. Once we arrived on the continent of Antarctica, we worked to collect a range of hosts from the Southern Ocean to screen these for the whole array of parasites,” she explains. 

No research of any kind on aquatic parasites has ever been done in Penguin Bukta and Akta Bukta, the specific areas where Prof Basson was based with other scientists and the rest of the Agulhas crew.

She adds: “Our research will contribute to the wider knowledge of parasites in marine environments, but specifically in this area where little to nothing is known.”

A chance of a lifetime 
“Antarctica was literally one of the top research destinations on my bucket list. Travelling to and working in Antarctica is a lifelong dream of mine. It was a chance of a lifetime that I could not miss out on,” says Prof Basson. 

Sharing her experience, she says a typical day on board the SA Agulhas II in Antarctica will start with a cup of good, quality coffee and a look at the prevailing weather on the stern of the ship. 

“One would always be amazed by the beautiful, ceaselessly changing water, the restless sea ice and the impressive ancient ice shelf in very invigorating temperatures, while an ethereal Snow Petrel swirls past and the occasional Adelie penguin comes to gaze and contemplate the presence of this large red structure floating in their habitat and obscuring their view. After tearing yourself away from this, the rest of the day would be spent either in the well-equipped laboratory working through collected samples, or else planning the next exciting collection in the intensely cold water.”

Remarkable journey 
To eternalise memories of this unique experience of almost three months, Prof Basson says that, “One cannot go without a fully charged camera with a large SD card, ready to capture the many facets of this exceedingly fragile but enchanting world of ice and sky, ever changing and all in innumerable shades of white”.

“This truly remarkable journey will forever be associated with a myriad of brilliant highlights.”

Finding it extremely difficult to single out a specific highlight, she listed a long list of memorable events, but as a scientist she will always remember “realising the wealth and cornucopia of microscopic life present in the southernmost of our oceans and seeing this first-hand under the microscope”.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept